Zacks Investment Research downgraded shares of R1 RCM (NASDAQ:RCM) from a hold rating to a sell rating in a report published on Wednesday morning.
According to Zacks, “R1 RCM Inc. offers financial services for the health care industries. The Company provides revenue cycle management and physician advisory services, as well as transforms and manages the commercial infrastructure of health care organizations. R1 RCM Inc., formerly known as Accretive Health, Inc., is headquartered in Chicago, Illinois. “
A number of other equities research analysts have also recently weighed in on the company. BidaskClub upgraded R1 RCM from a hold rating to a buy rating in a report on Thursday, January 11th. Robert W. Baird restated a hold rating and issued a $5.00 price target on shares of R1 RCM in a report on Tuesday, September 26th.
R1 RCM (NASDAQ:RCM) last released its quarterly earnings results on Tuesday, October 31st. The financial services provider reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.05). R1 RCM had a negative return on equity of 9.33% and a negative net margin of 1.32%. equities research analysts forecast that R1 RCM will post -0.12 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the stock. Paradigm Capital Management Inc. NY lifted its stake in R1 RCM by 14.8% in the 3rd quarter. Paradigm Capital Management Inc. NY now owns 6,967,900 shares of the financial services provider’s stock valued at $25,851,000 after buying an additional 900,753 shares in the last quarter. Vanguard Group Inc. purchased a new stake in R1 RCM in the 2nd quarter valued at approximately $10,550,000. State Street Corp purchased a new stake in R1 RCM in the 2nd quarter valued at approximately $5,327,000. Northern Trust Corp lifted its stake in R1 RCM by 46.4% in the 2nd quarter. Northern Trust Corp now owns 1,145,411 shares of the financial services provider’s stock valued at $4,295,000 after buying an additional 362,773 shares in the last quarter. Finally, Unterberg Capital LLC purchased a new stake in R1 RCM in the 3rd quarter valued at approximately $2,579,000. 47.41% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2018/01/21/r1-rcm-rcm-downgraded-by-zacks-investment-research-to-sell.html.
About R1 RCM
R1 RCM Inc, formerly Accretive Health, Inc, is a provider of revenue cycle management (RCM) and physician advisory services (PAS) to healthcare providers. The Company is engaged in providing management services of revenue cycle operations for the United States-based hospitals and other medical services providers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.